研究单位：[1]Lee's Pharmaceutical Limited[2]West China Hospital[3]The Second Affiliated Hospital of Guangxi Medical University,Nanning,Guangxi,China[4]Affiliated Hospital of Guizhou Medical University,Guiyang,Guizhou,China[5]First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China[6]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China[7]Beijing Friendship Hospital, Capital Medical University,Beijing,China[8]West China Hospital, Sichuan University,Chengdu,China
This prospective, randomized controlled study is intended to enroll 152 patients in the early stages of donor kidney transplantation at six clinical centers in China between January 2023 and January 2024. All patients meeting the inclusion criteria were randomly assigned 1:1 to either Mizoribine or Mycophenolate Mofetil for 12 months. At the baseline of follow-up (before enrollment) and each follow-up point, all clinical indicators of patients were recorded to measure the therapeutic effect.
